Martin Babler
Directeur/Membre du Conseil chez OMEGA ALPHA SPAC
Fortune : 1 M $ au 30/06/2024
Profil
Mr. Martin Babler is an Independent Director at 89bio, Inc., a Chairman, President & Chief Executive Officer at Alumis, Inc., an Independent Director at Prelude Therapeutics, Inc. and an Independent Director at Omega Alpha SPAC.
He is on the Board of Directors at 89bio, Inc., Prelude Therapeutics, Inc., Omega Alpha SPAC, Biotechnology Innovation Organization and Sardona Therapeutics, Inc. Mr. Babler was previously employed as an Independent Director by Neoleukin Therapeutics, Inc., an Independent Director by ZS Pharma, Inc., a President, Chief Executive Officer & Director by Principia Biopharma, Inc., an Independent Director by Infinity Pharmaceuticals, Inc., a President & Chief Executive Officer by Talima Therapeutics, Inc., a Vice President-Immunology Sales & Marketing by Genentech, Inc., and a Principal by Eli Lilly & Co.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. 0,18% | 01/07/2024 | 90 804 ( 0,18% ) | 1 M $ | 30/06/2024 |
| 14/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Martin Babler
| Sociétés | Poste | Début |
|---|---|---|
| OMEGA ALPHA SPAC | Directeur/Membre du Conseil | 01/09/2020 |
| PRELUDE THERAPEUTICS INCORPORATED | Directeur/Membre du Conseil | 19/07/2021 |
| 89BIO, INC. | Directeur/Membre du Conseil | 13/04/2024 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Directeur/Membre du Conseil | - |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. | Directeur Général | 23/09/2021 |
| Sardona Therapeutics, Inc. | Directeur/Membre du Conseil | - |
Anciens postes connus de Martin Babler
| Sociétés | Poste | Fin |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Directeur Général | 01/10/2020 |
| ZS PHARMA INC | Directeur/Membre du Conseil | 17/12/2015 |
| INFINITY PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/03/2014 |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
 | Health Technology |
| 89BIO, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Talima Therapeutics, Inc.
 Talima Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talima Therapeutics, Inc. operated as a drug delivery company. It had developed a micro implant delivery technology for the localized application of small molecule drugs. The firm’s product was in phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the toenails. The company was founded in 2004 and was headquartered in San Carlos, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA. | Finance |
| Sardona Therapeutics, Inc. |
